Changes in Hong Kong stocks | Sihuan Pharmaceutical (00460) rose more than 6%, net profit pre-increased by no less than 217.2% in the first half of the year, and the company's medical and aesthetic business entered a phase of rapid expansion

The Zhitong Finance App learned that Sihuan Pharmaceutical (00460) rose by more than 6%. As of press release, it had risen 6.47% to HK$0.905, with a turnover of HK$36.9359 million.

According to the news, recently, Sihuan Pharmaceutical's performance is forecast. The Group expects to earn no less than RMB 1.14 billion in revenue for the six months ending June 30, 2026, which is roughly the same as the same period last year; net profit for the period obtained will not be less than RMB 210 million, an increase of no less than 217.2% over the same period last year. During this period, the Group's medical and aesthetic sector continued to benefit from the steady growth of the core product Lotivo® (botulinum toxin), as well as the continued release of regenerative medical and aesthetic products (including beauty acupuncture and teenage acupuncture) and functional medical and aesthetic products, driving related business revenue growth.

Great Wall Securities pointed out that Sihuan Pharmaceutical's medical and aesthetic business has successfully established a layout of five core categories covering “botulic+hyaluronic acid+regenerated materials+optoelectronic equipment+kinetics”. The bank believes that the company's medical and aesthetic business has entered a stage of rapid expansion, profits from innovative drugs, other pharmaceuticals, and generic drug businesses are expected to improve, and the company's operations have reached an inflection point.